Accordingly, the inhibition of CCL3-mediated signal by the treatment with an allosteric inhibitor of CCL3 receptor, maraviroc, efficiently prevented the development of CML but failed to eradicate CML LICs3. The gene discussed is CCL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.